Morgan Stanley raised the firm’s price target on Tenet Healthcare (THC) to $232 from $225 and keeps an Overweight rating on the shares. Tenet delivered “another strong earnings report” and higher margins and improving free cash flow are supporting capital investment to add higher acuity service lines in the hospital segment and exceed targeted M&A in Ambulatory Surgical Centers, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $238 from $221 at Guggenheim
- Tenet Healthcare Reports Strong Q3 2025 Results
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare
- Tenet Healthcare price target raised to $230 from $225 at BofA
- Morning Movers: UPS and PayPal jump following quarterly reports